17/07/2026 European Commission approved JASCAYD® as a treatment option for IPF and PPF in the EU Novartis received FDA traditional approval for Fabhalta® for the treatment of primary IgAN European Commission approved JASCAYD® as a treatment option for IPF and PPF in the EU (Ref) Boehringer Ingelheim announced that the European Commission had granted marketing authorization for JASCAYD® (nerandomilast; PDE4B inhibitor) for the treatment of adults with idiopathic pulmonary fibr

18/06/2026 GRI Bio secured FDA Orphan Drug Designation for Tazarotene in Idiopathic Pulmonary Fibrosis GRI Bio secured FDA Orphan Drug Designation for Tazarotene in Idiopathic Pulmonary Fibrosis (Ref) GRI Bio announced that the US FDA had granted Orphan Drug Designation to Tazarotene (GRI-062; oral RARβ/γ-selective agonist) for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The designation marked a significant regulatory milestone and provided a potential pathway to se

03/06/2026 Johnson & Johnson late-breaking results showed nipocalimab significantly reduced SLE disease activity in a Phase 2 study Johnson & Johnson announced biomarker exploratory analyses from a Phase 2 study of nipocalimab in moderate-to-severe SjD Argenx presented efgartigimod data showing long-term sustained patient benefit in myositis and SjD at EULAR-2026 JJP Biologics announces positive interim Phase 1b data for nebaprubart in Linear IgA Disease Spyre Therapeutics an